OTC · CIK 0001563665
HRGN Harvard Apparatus Regenerative Technology, Inc.
Insider trading from SEC Form 4. Last filing 17 d ago. Close $2.30 on Oct 9, 2026, +130% from the 52-week low and -2% from the high.
Last 90 days
Net insider value
+$394k
more bought than sold
Buys
1
$394k by 1 insider
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company
Price and insider trades, last year
HRGNOct 9, 2026 · close 2.30
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Harvard Apparatus Regenerative Technology, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 47Moderate | Junli He CEO buy | $394k 368,630 shares | +38% | - | |
| 38Weak | Junli He CEO buy | $5,100 3,000 shares | +1% | +26% from low-47% from high | |
| 33Weak | Junli He CEO buy | $594 300 shares | +0% | +48% from low-65% from high | |
| 38Weak | Junli He CEO buy | $21k 11,225 shares | +4% | +27% from low-70% from high | |
| 33Weak | Junli He CEO buy | $6,966 4,050 shares | +2% | +23% from low-71% from high | |
| 20Weak | Junli He CEO buy | $6,598 2,299 shares | +1% | - |
Transactions
The last 25 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 11, 2026 | Junli He CEO | CConversion Common Stock | +683,725 | $1.05 | $718k | 964,300 | 17 d ago |
| Sep 11, 2026 | Junli He CEO | POpen-market purchase Common Stock | +361,905 | $1.05 | $380k | 1,326,205 | 17 d ago |
| Sep 15, 2026 | Junli He CEO | POpen-market purchase Common Stock | +6,725 | $2.15 | $14k | 1,332,930 | 17 d ago |
| Sep 11, 2026 | Junli He CEO | CConversion Bridge Note (04/14/2026)derivative | -310,000 | - | - | 0 | 17 d ago |
| Sep 11, 2026 | Junli He CEO | CConversion Bridge Note (05/13/2026)derivative | -205,378 | - | - | 0 | 17 d ago |
| Sep 11, 2026 | Junli He CEO | CConversion Bridge Note (07/16/2026)derivative | -202,533 | - | - | 0 | 17 d ago |
| Nov 25, 2025 | Junli He CEO | POpen-market purchase Common Stock | +3,000 | $1.70 | $5,100 | 280,575 | Dec 1, 2025 |
| Sep 30, 2025 | Junli He CEO | POpen-market purchase Common Stock | +300 | $1.98 | $594 | 277,575 | Oct 1, 2025 |
| Sep 2, 2025 | Junli He CEO | POpen-market purchase Common Stock | +11,225 | $1.85 | $21k | 277,275 | Sep 24, 2025 |
| Aug 21, 2025 | Junli He CEO | POpen-market purchase Common Stock | +4,050 | $1.72 | $6,966 | 266,050 | Sep 2, 2025 |
| Jun 27, 2025 | David Green director | AGrant or award Stock Option (right to buy)derivative | +18,590 | $0.00 | $0 | 18,590 | Jul 1, 2025 |
| Jun 27, 2025 | Mao Zhang director | AGrant or award Stock Option (right to buy)derivative | +18,590 | $0.00 | $0 | 18,590 | Jul 1, 2025 |
| Jun 27, 2025 | James E. Shmerling director | AGrant or award Stock Option (right to buy)derivative | +18,590 | $0.00 | $0 | 18,590 | Jul 1, 2025 |
| Jun 27, 2025 | Herman Sanchez director | AGrant or award Stock Option (right to buy)derivative | +18,590 | $0.00 | $0 | 18,590 | Jul 1, 2025 |
| Jun 27, 2025 | Ronald J Packard director | AGrant or award Stock Option (right to buy)derivative | +18,590 | $0.00 | $0 | 18,590 | Jul 1, 2025 |
| Jun 27, 2025 | Ting Li director | AGrant or award Stock Option (right to buy)derivative | +18,590 | $0.00 | $0 | 18,590 | Jul 1, 2025 |
| Jun 27, 2025 | Jing Chen director | AGrant or award Stock Option (right to buy)derivative | +18,590 | $0.00 | $0 | 18,590 | Jul 1, 2025 |
| Jun 27, 2025 | Ting Li director | AGrant or award Stock Option (right to buy)derivative | +15,227 | $0.00 | $0 | 15,227 | Jul 1, 2025 |
| Jun 27, 2025 | Ronald J Packard director | AGrant or award Stock Option (right to buy)derivative | +15,227 | $0.00 | $0 | 15,227 | Jul 1, 2025 |
| Jun 27, 2025 | David Green director | AGrant or award Stock Option (right to buy)derivative | +15,227 | $0.00 | $0 | 15,227 | Jul 1, 2025 |
| Jun 27, 2025 | Herman Sanchez director | AGrant or award Stock Option (right to buy)derivative | +15,227 | $0.00 | $0 | 15,227 | Jul 1, 2025 |
| Jun 27, 2025 | Jing Chen director | AGrant or award Stock Option (right to buy)derivative | +15,227 | $0.00 | $0 | 15,227 | Jul 1, 2025 |
| Jun 27, 2025 | James E. Shmerling director | AGrant or award Stock Option (right to buy)derivative | +15,227 | $0.00 | $0 | 15,227 | Jul 1, 2025 |
| Jun 27, 2025 | Mao Zhang director | AGrant or award Stock Option (right to buy)derivative | +15,227 | $0.00 | $0 | 15,227 | Jul 1, 2025 |
| Dec 24, 2024 | Junli He CEO | POpen-market purchase Common Stock | +2,299 | $2.87 | $6,598 | 262,000 | Jan 2, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jing Chendirector
- David Greendirector
- Junli HeCEO
- Ting Lidirector
- Ronald J Packarddirector
- Herman Sanchezdirector
- James E. Shmerlingdirector
- Mao Zhangdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.